DaShenLin Pharmaceutical Group Co., Ltd. (SHA: 603233)
13.42
-0.38 (-2.75%)
Sep 6, 2024, 3:00 PM CST
DaShenLin Pharmaceutical Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 906.67 | 1,166 | 1,036 | 791.23 | 1,062 | 702.66 | Upgrade
|
Depreciation & Amortization | 1,526 | 1,429 | 1,288 | 1,149 | 170.77 | 142.65 | Upgrade
|
Other Amortization | 292.72 | 267.32 | 243.75 | 218.08 | 169.03 | 149.79 | Upgrade
|
Loss (Gain) From Sale of Assets | 4.33 | -3.43 | -18.73 | -5.63 | 2.53 | 1.64 | Upgrade
|
Asset Writedown & Restructuring Costs | 6.21 | 6.21 | - | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | -0.62 | -10.94 | 12.89 | -44 | -20.91 | -16.32 | Upgrade
|
Provision & Write-off of Bad Debts | 12.08 | 15.92 | 23.6 | 11.49 | 5.6 | 4.95 | Upgrade
|
Other Operating Activities | 394.58 | 388.19 | 294.24 | 247.49 | 55.02 | 35.58 | Upgrade
|
Change in Accounts Receivable | -471.2 | -364.73 | -953.44 | -317.98 | -75.05 | 68.52 | Upgrade
|
Change in Inventory | 54.09 | -104.16 | -157.39 | -745.93 | -539.61 | -65.85 | Upgrade
|
Change in Accounts Payable | 753.59 | 389.07 | 1,967 | 235.18 | 1,113 | 689.18 | Upgrade
|
Change in Other Net Operating Assets | 13.47 | 19.04 | 48.54 | 65.63 | 14.45 | 9.63 | Upgrade
|
Operating Cash Flow | 3,464 | 3,174 | 3,757 | 1,555 | 1,954 | 1,708 | Upgrade
|
Operating Cash Flow Growth | -9.21% | -15.51% | 141.58% | -20.42% | 14.41% | 95.48% | Upgrade
|
Capital Expenditures | -1,829 | -1,797 | -1,035 | -1,295 | -792.32 | -501.41 | Upgrade
|
Sale of Property, Plant & Equipment | 27.39 | 14.64 | 37.37 | 21.61 | 12.35 | 7.55 | Upgrade
|
Cash Acquisitions | -475.53 | -502.3 | -305.25 | -529.82 | -289.75 | -359.54 | Upgrade
|
Investment in Securities | -44.82 | -2.16 | 5.54 | 814.11 | -19.16 | -819.96 | Upgrade
|
Other Investing Activities | -8.88 | -11.8 | 3.17 | 21.35 | 17.64 | 14.71 | Upgrade
|
Investing Cash Flow | -2,336 | -2,303 | -1,294 | -967.7 | -1,071 | -1,659 | Upgrade
|
Short-Term Debt Issued | - | 16 | - | - | 1,570 | - | Upgrade
|
Long-Term Debt Issued | - | 1,094 | 1,095 | 145.63 | - | 1,085 | Upgrade
|
Total Debt Issued | 2,036 | 1,110 | 1,095 | 145.63 | 1,570 | 1,085 | Upgrade
|
Short-Term Debt Repaid | - | -4.9 | - | - | -118.8 | - | Upgrade
|
Long-Term Debt Repaid | - | -2,388 | -1,655 | -1,321 | - | -381.38 | Upgrade
|
Total Debt Repaid | -2,758 | -2,392 | -1,655 | -1,321 | -118.8 | -381.38 | Upgrade
|
Net Debt Issued (Repaid) | -722.4 | -1,282 | -560.15 | -1,175 | 1,451 | 703.62 | Upgrade
|
Issuance of Common Stock | - | - | - | 13.25 | 100.01 | - | Upgrade
|
Repurchase of Common Stock | -41.17 | -0.95 | -0.11 | -0.44 | - | - | Upgrade
|
Common Dividends Paid | -373.46 | -604.51 | -420.29 | -534.28 | -333.27 | -253.39 | Upgrade
|
Other Financing Activities | 170.97 | 238.15 | 46.98 | 84.37 | -8.41 | -30.05 | Upgrade
|
Financing Cash Flow | -966.07 | -1,649 | -933.57 | -1,612 | 1,209 | 420.18 | Upgrade
|
Net Cash Flow | 161.51 | -778.78 | 1,529 | -1,025 | 2,092 | 469.31 | Upgrade
|
Free Cash Flow | 1,634 | 1,377 | 2,722 | 260.05 | 1,162 | 1,206 | Upgrade
|
Free Cash Flow Growth | -11.48% | -49.40% | 946.64% | -77.61% | -3.71% | 277.88% | Upgrade
|
Free Cash Flow Margin | 6.31% | 5.61% | 12.81% | 1.55% | 7.97% | 10.83% | Upgrade
|
Free Cash Flow Per Share | 1.44 | 1.22 | 2.39 | 0.23 | 1.03 | 1.09 | Upgrade
|
Cash Income Tax Paid | 1,254 | 1,108 | 939.01 | 897.77 | 846.9 | 776.34 | Upgrade
|
Levered Free Cash Flow | 2,889 | 2,261 | 2,191 | 412.54 | 740.11 | 1,053 | Upgrade
|
Unlevered Free Cash Flow | 3,041 | 2,411 | 2,336 | 545.07 | 747.29 | 1,073 | Upgrade
|
Change in Net Working Capital | -2,117 | -1,370 | -804.95 | 281.16 | -333.76 | -699.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.